Literature DB >> 18635578

Dementia of the Alzheimer type.

Jessica J Jalbert1, Lori A Daiello, Kate L Lapane.   

Abstract

Dementia of the Alzheimer type is a progressive, fatal neurodegenerative condition characterized by deterioration in cognition and memory, progressive impairment in the ability to carry out activities of daily living, and a number of neuropsychiatric symptoms. This narrative review summarizes the literature regarding descriptive epidemiology, clinical course, and characteristic neuropathological changes of dementia of the Alzheimer type. Although there are no definitive imaging or laboratory tests, except for brain biopsy, for diagnosis, brief screening instruments and neuropsychiatric test batteries used to assess the disease are discussed. Insufficient evidence exists for the use of biomarkers in clinical practice for diagnosis or disease management, but promising discoveries are summarized. Optimal treatment requires both nonpharmacological and pharmacological interventions, yet none have been shown to modify the disease's clinical course. This review describes the current available options and summarizes promising new avenues for treatment. Issues related to the care of persons with dementia of the Alzheimer type, including caregiver burden, long-term care, and the proliferation of dementia special care units, are discussed. Although advances have been made, more research is needed to address the gaps in our understanding of the disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18635578     DOI: 10.1093/epirev/mxn008

Source DB:  PubMed          Journal:  Epidemiol Rev        ISSN: 0193-936X            Impact factor:   6.222


  25 in total

1.  Confirmatory factor analysis of the ADNI Neuropsychological Battery.

Authors:  Lovingly Quitania Park; Alden L Gross; Donald G McLaren; Judy Pa; Julene K Johnson; Meghan Mitchell; Jennifer J Manly
Journal:  Brain Imaging Behav       Date:  2012-12       Impact factor: 3.978

Review 2.  The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics.

Authors:  Eric Karran; Marc Mercken; Bart De Strooper
Journal:  Nat Rev Drug Discov       Date:  2011-08-19       Impact factor: 84.694

3.  Cognitive impairment in humanized APP×PS1 mice is linked to Aβ(1-42) and NOX activation.

Authors:  Annadora J Bruce-Keller; Sunita Gupta; Alecia G Knight; Tina L Beckett; Jessica M McMullen; Paulina R Davis; M Paul Murphy; Linda J Van Eldik; Daret St Clair; Jeffrey N Keller
Journal:  Neurobiol Dis       Date:  2011-07-28       Impact factor: 5.996

4.  [Alzheimer's disease].

Authors:  U Yilmaz
Journal:  Radiologe       Date:  2015-05       Impact factor: 0.635

Review 5.  Rivastigmine transdermal patch 13.3 mg/24 h: a review of its use in the management of mild to moderate Alzheimer's dementia.

Authors:  James E Frampton
Journal:  Drugs Aging       Date:  2014-08       Impact factor: 3.923

6.  Locus Coeruleus Ablation Exacerbates Cognitive Deficits, Neuropathology, and Lethality in P301S Tau Transgenic Mice.

Authors:  Termpanit Chalermpalanupap; Jason P Schroeder; Jacki M Rorabaugh; L Cameron Liles; James J Lah; Allan I Levey; David Weinshenker
Journal:  J Neurosci       Date:  2017-11-13       Impact factor: 6.167

7.  Alzheimer's disease is type 3 diabetes-evidence reviewed.

Authors:  Suzanne M de la Monte; Jack R Wands
Journal:  J Diabetes Sci Technol       Date:  2008-11

8.  NOX activity is increased in mild cognitive impairment.

Authors:  Annadora J Bruce-Keller; Sunita Gupta; Taryn E Parrino; Alecia G Knight; Philip J Ebenezer; Adam M Weidner; Harry LeVine; Jeffrey N Keller; William R Markesbery
Journal:  Antioxid Redox Signal       Date:  2010-06-15       Impact factor: 8.401

9.  Reduced cortical BACE1 content with one bout of exercise is accompanied by declines in AMPK, Akt, and MAPK signaling in obese, glucose-intolerant mice.

Authors:  R E K MacPherson; P Baumeister; W T Peppler; D C Wright; J P Little
Journal:  J Appl Physiol (1985)       Date:  2015-09-24

10.  Private costs almost equal health care costs when intervening in mild Alzheimer's: a cohort study alongside the DAISY trial.

Authors:  Rikke Søgaard; Jan Sørensen; Frans B Waldorff; Ane Eckermann; Dorthe V Buss; Gunhild Waldemar
Journal:  BMC Health Serv Res       Date:  2009-11-25       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.